practical blood bank lab 7 antibody identification
TRANSCRIPT
Antibody Presence
Presence of an antibody may be indicated by the following serological tests:
1.A discrepancy in the results of cell and serum ABH grouping.
2.A positive test for unexpected antibodies.
3.A positive direct Coomb’s test.
4.An incompatible major cross match.
The Basics..… As we said in the previous lecture,
Antibody Screens use 2 or 3 Screening Cells to “detect” if antibodies are present in the serum
If antibodies are detected, then they should be identified…
Why do we need to identify? Antibody identification is an important
component of compatibility testing It will identify any unexpected antibodies in
the patient’s serum If a person with an antibody is exposed to
donor cells with the corresponding antigen, serious side effects can occur (i.e. transfusion reactions).
Key Concepts In blood banking, we test “knowns” with
“unknowns”:-
When detecting/screening and/or identifying antibodies, we test patient serum (unknown that contain blood bank antibodies) with reagent RBCs (known)
Known: Unknown:
Reagent RBCs + patient serum
Reagent antisera + patient RBCs
Known: Unknown:
Reagent RBCs + patient serum
Reagent antisera + patient RBCs
Reagent RBCs Screening Red Cells and Panel Red
Cells are the same with minor differences: Screening red cells
Antibody detection/screening Sets of only 2 or 3 vials
Panel red cells Antibody identification At least 10 vials/set
Antibody Panel vs. Screen An antibody panel is just an extended version of an
antibody screen The screen only uses 2-3 red cells:
Antibody Panel While antibody panel usually includes at
least 10 panel cells: (8-16 group O RBCs)
Group O red blood cells obtained from donors
Panel Red Cells Each of the panel cells has been
antigen typed (shown on antigram) + refers to the presence of the antigen 0 refers to the absence of the antigen
IS Phase Perform immediate spin (IS) and grade
agglutination; inspect for hemolysis Record the results in the appropriate space as
shown.
(LISS )37°C Phase 2 drops of LISS are added, mixed and incubated
for 10-15 minutes. Centrifuge and check for agglutination Record results as previous but now fill the 37°C
lane.
Agglutination Viewer
IAT Phase (or AHG) Indirect Antiglobulin Test (IAT) – we’re testing
whether or not possible antibodies in patient’s serum will react with RBCs in vitro
To do this we use the Anti-Human Globulin reagent (AHG) Polyspecific AHG Monospecific Anti-IgG Monospecific Anti-Complement
IAT (AHG) Phase Wash red cells 3X with saline (manual or
automated (cell washer)) Add 2 drops of AHG and gently mix
Centrifuge Read for agglutination Record reactions
Guidelines Again, it’s important to look at:
Autocontrol Negative - alloantibody Positive – autoantibody or DTR (i.e. alloantibodies)
Phases IS – cold (IgM) 37° - cold (some have higher thermal range) or warm reacting AHG – warm (IgG)…significant!!
Reaction strength 1 consistent strength – one antibody Different strengths – multiple antibodies or dosage
Matching the pattern Single antibodies usually shows a pattern that matches one of the Multiple antibodies are more difficult to match because they often show mixed
reaction strengths
Rule of three The rule of three rule of three must be met to confirm the
presence of the antibody How is it demonstrated?
Patient serum MUST be: Positive with 3 panel cells with the antigen,
+ve reaction. Negative with 3 cells without the antigen and
should not be reacting.
What if the “rule of three” is not fulfilled? If there are not enough cells in the panel to fulfill the
rule, then additional cells from another panel could be used
Better to carry different lot numbers of panel cells
Patient Antigen Typing (Phenotyping)
In addition to the rule of three, antigen typing the patient red cells can also confirm an antibody
How is this done? Only perform this if the patient has NOT been recently
transfused (donor cells could react (chimera)). If reagent antisera (of the suspected antibody) is added
to the patient RBCs, a negative reaction should result…Why?
Multiple antibodies Multiple antibodies may be more of a challenge
than a single antibody Why?
Reaction strengths can vary Matching the pattern is difficult
So what we have to do? Several procedures can be performed to
identify multiple antibodies Selected Cells Neutralization Chemical treatment
Proteolytic enzymes Sulfhydryl reagents
1 -Selected Red Cells Selected cells are chosen from other panel or screening cells to
confirm or eliminate the antibody. The cells are “selected” from other panels because of their
characteristics. The number of selected cells needed depends on how may
antibodies are identified. Every cell should be positive only for each of the antibodies and
negative for the remaining suspicious antibodies For example:
Let’s say you ran a panel and identified 3 different antibodies (you cannot rule out): anti-S, anti-Jka, and anti-P1
Selected cells could help…
2 -Neutralization Some antibodies may be neutralized as a way of confirmation Commercial “substances” bind to the antibodies in the patient
serum, causing them to show no reaction when tested with the corresponding antigen (in panel)
Common substances P1 substance (derived from hydatid cyst fluid) Lea and Leb substance (soluble antigen found in plasma and
saliva) I substance can be found in breast milk
**you should be aware that many of these substances neutralize COLD antibodies; Cold antibodies can sometimes mask more clinically significant antibodies (IgG), an important reason to use neutralization techniques
3 -Again: Proteolytic Enzymes Can be used to enhance or destroy certain blood
group antigens Several enzymes exist:
Ficin (figs) Bromelin (pineapple) Papain (papaya)
In addition, enzyme procedures may be One-step Two-step
Enzymes
Enzymes remove the sialic acid from the RBC membrane, thus “destroying” it and allowing other antigens to be “enhanced” Antigens destroyed: M, N, S, s, Duffy Antigens enhanced: Rh, Kidd, Lewis, I, and P
One-stageOne-stage Enzyme is added directly to the serum/panel cell mixture
Two-stageTwo-stage Panel cells are pre-treated with an enzyme, and washed Patient serum is added to treated panel cells and tested
If there is no agglutination after treatment, then it is assumed the enzymes destroyed the antigen
Sulfhydryl Reagents Cleave the disulfide bonds of IgM molecules and help
differentiate between IgM and IgG antibodies Good to use when you have both IgG and IgM
antibodies (warm/cold) Dithiothreitol (DTT) is a thiol and will denature Kell antigens 2-mercaptoethanol (2-ME)
Autoantibodies Autoantibodies can be cold or warm reacting
A positive autocontrol or DAT may indicate that an auto-antibody is present
Sometimes the autocontrol may be positive, but the antibody screening may be negative, meaning something is coating the RBC
Getting a positive DAT We have focused a lot on the IAT used in antibody
screening and ID, but what about the DAT?
The direct antiglobulin test )DAT( tests for the in vivo coating of RBCs with antibody (in the body)
AHG is added to washed patient red cells to determine this
What can the DAT tell us? Although not always performed in routine pretransfusion
testing, a positive DAT can offer valuable information If the patient has been transfused, the patient may have an
alloantibody coating the transfused cells
If the patient has NOT been transfused, the patient may have an autoantibody coating their own cells
Identifying autoantibodies
Auto-antibodies can sometimes “mask” clinically significant allo-antibodies, so it’s important to differentiate between auto- and allo-antibodies
Cold autoantibodies React at room temperature with most (if not
all) of the panel cells and give a positive autocontrol
The DAT is usually positive with anti-C3 AHG (detects complement)
Could be due to Mycoplasma pneumoniae, infectious mono, or cold agglutinin disease
Avoiding reactivity Cold Autoantibodies can be a trouble at times.
Here are a few ways to avoid a reaction: Use anti-IgG AHG instead of polyspecific. Most cold
antibodies react with polyspecific AHG AHG because they fix complement
Skipping the IS phase avoids the attachment of cold autoantibodies to the red cells
Use 22% BSA instead of LISS
Other techniques If the antibodies remain, then prewarmed
techniques can be performed: Red cells, serum, and saline are incubated at 37°
before being combined Autoadsorption is another technique in
which the autoantibody is removed from the patients serum using their own red cellsThe serum can be used to identify any underlying
alloantibodies
Warm autoantibodies More common that cold autoantibodies Positive DAT due to IgG antibodies coating the
red cell Again, the majority of panel or screening cells
will be positive
Warm autoantibodies Cause warm autoimmune hemolytic anemia
(WAIHA)… How do you get a warm autoantibody?
Idiopathic Known disorder (SLE, RA, leukemias, pregnancy,
infectious diseases, etc) Medications
Several techniques are used when warm autoantibodies are suspected…
Elution (whenever DAT is positive)Elution techniques “free” antibodies from
the sensitized red cells so that the antibodies can be identified
Elution The eluate is a term used for the removed
antibodies Testing the eluate is useful in investigations of
positive DATs HDN Transfusion reactions Autoimmune disease
The red cells can also be used after elution for RBC phenotyping if needed
When tested with panel cells, the eluate usually remains reactive with all cells if a warm autoantibody is present
Elution Methods Acid elutions (glycine acid)
Most common Lowers pH, causing antibody to dissociate
Organic solvents (ether, chloroform) Dissolve bilipid layer of RBC
Heat (conformational change) Freeze-Thaw (lyses cells)
Adsorption Adsorption procedures can be used to investigate
underlying alloantibodies After the patient RBCs are incubated, the adsorbed
serum is tested with panel cells to ID the alloantibody (if present)
Adsorption Two types:
Autoadsorption No recent transfusion Autoantibodies are removed using patient RBCs, so
alloantibodies can be identified Allogenic (Differential) adsorption
If recently transfused Uses other cells with the patients serum
Summary If an unexpected antibody is detected in a patient’s
serum or plasma it must be identified. Once identified the clinical significance must be
determined.
Summary If the antibody is clinically significant antigen
negative donors must be found and crossmatched for the patient, a Coomb’s crossmatch must be done.
If the antibody is not clinically significant it is not necessary to provide antigen negative blood, but the donors must be compatible by the Coomb’s crossmatch.
Providing Compatible Donor Units Once an antibody has been identified, the next task
is to provide appropriate units of RBCs for transfusion.
When clinically insignificant antibodies are
detected, use of crossmatch-compatible RBCs is appropriate.
Providing Compatible Donor Units No further testing is needed to confirm compatibility when
the antibody is anti-M, anti-N, anti-Pi. Lea, or Leb.
However, when a clinically significant antibody is identified, the blood must be cross-match compatible and confirmed as antigen-negative with reagent antisera.
Example Knowledge of the incidence of antigens is useful for
determining how many units of blood to screen or cross match for patients with antibodies.
If a patient with an anti-Jk(a-) needed 4 units of blood, how many units would need to be tested to find them?
Jk (a+)= 0.77 Jk (a-) = 0.23
4 units Jk(a-) blood needed = 17.4 units 0.23 incidence of
Jk(a-) In this case, testing 17 or 18 random units should yield 4
Jk(a-) units.
Example 2 The same calculations can be used when multiple
antibodies are present if the antigen frequencies are first multiplied together.
E.g. a patient with an anti-K and anti-Jka, 10 random units would need to be tested to find 2 that are compatible.
Jk(a+) = 0.77 K positive = 0.09
Jk(a-) = 0.23 K negative = 0.91 Jk(a-) (0.23) X K negative (0.91) = 0.20 Jk(a-) and K
negative
2 units needed = 10 units 0.20 Jk(a-) and Kell negative